Nivolumab for neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Also followed for narrower conditions: Carcinoma, Transitional Cell, Sarcoma, Squamous Cell Carcinoma of Head and Neck

Why this status

  1. 2 Apr 2019: Trial registered, NCT03899155
  2. 9 Aug 2019: Trial started, NCT03899155

The trials

NCT03899155: Pan Tumor Rollover Study

State
Under way
Phase
Phase 2
People
1,500 planned
Started
9 Aug 2019
Primary completion
25 Aug 2029
Arms
A1: Nivolumab Monotherapy Dose 1, A2: Nivolumab Monotherapy Dose 2, D4: Nivolumab + Bevacizumab
Results
None posted
  1. 2 Apr 2019: Trial registered
  2. 9 Aug 2019: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Also known as Nivolumab 3 mg/kg + platinum-based chemotherapy (2 cycles, neoadjuvant), Opdivo, Opdivo qvantig component nivolumab, Opdualag component nivolumab.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.